Future Directions for Fenfluramine in CDKL5 Deficiency Disorder

As therapeutic development in CDKL5 deficiency disorder (CDD) continues to advance, clinicians are beginning to consider how emerging trial findings may translate into day-to-day treatment decisions. For patients with refractory seizures and substantial developmental comorbidities, new options must be evaluated not only for seizure reduction, but also for durability, safety, and how they fit within existing treatment algorithms.

In this Special Report, Sam Amin, MD, reflects on findings from a recent phase 3 randomized, double-blind, placebo-controlled study evaluating fenfluramine in pediatric and adult patients with CDD. As a study author, Amin offers perspective on how the data may inform future management strategies, particularly given fenfluramine’s established clinical development programs in Dravet syndrome and Lennox-Gastaut syndrome.

In this final episode, Amin discusses how the study’s positive efficacy and safety findings may influence clinical practice and where additional research is still needed. He highlights the importance of collecting long-term outcomes data to better understand fenfluramine’s safety, durability of effect, and eventual positioning in the broader CDD treatment landscape.